At Oncosence we target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds

Healthy cells use the preprogrammed mechanism of senescence to prevent becoming malignant. In contrast to normal cells, one of the hallmarks of cancer cells is the capability to escape senescence, thus acquiring a limitless replicative potential that is the prelude to invasion, metastasis and additional features of malignancy. At Oncosence we screen and develop compounds that selectively enhance senescence in cancer cells. However, recent advances suggest that if senescent tumour cells are not cleared from the tumors, they may promote tumour progression and metastasis we screen and develop senolytic agents that specifically target senescent cells. This two punch approach stops cancer growth by driving cancer cells in to senescent state and consecutively clears cancer cells in senescent state.